Autopsy report · NCT00074490

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

“Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 6 months after it had already started.
• Ran for about 13 years 7 months before it stopped.
• 442 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Lymphoma; Leukemia; Myeloproliferative Disorders; Multiple Myleoma; Myelodysplastic Syndrome

Interventions

Rituximab; Fludarabine; Etoposide; Doxorubicin; Vincristine; Cyclophosphamide

Participants

442

Sites

2

Countries

United States

Trials that died the same way

• Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
  “Early Closure due to rare patient population” (59% match in meaning)
• A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
  “An arm closed due to lack of efficacy” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.